{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:00:40Z","timestamp":1773939640338,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.12.001","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:20:15Z","timestamp":1765354815000},"page":"e223-e228.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly S.","family":"Chien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-3263","authenticated-orcid":false,"given":"Deborah","family":"McCue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-2264","authenticated-orcid":false,"given":"Danielle E.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Bazinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Bouligny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry A.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2025.12.001_bib0001","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/leu.2014.124","article-title":"DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies","volume":"28","author":"Im","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2025.12.001_bib0002","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.clml.2025.12.001_bib0003","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.12.001_bib0004","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"DiNardo","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2025.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.12.001_bib0006","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.12.001_bib0007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/leu.2011.298","article-title":"Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a mayo clinic study of 277 patients","volume":"26","author":"Patnaik","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.12.001_bib0008","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.clml.2025.12.001_bib0009","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov"},{"issue":"6127","key":"10.1016\/j.clml.2025.12.001_bib0010","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1231677","article-title":"(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible","volume":"339","author":"Losman","year":"2013","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.clml.2025.12.001_bib0011","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","article-title":"Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML","volume":"122","author":"Chaturvedi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.12.001_bib0012","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.2013.50.2047","article-title":"Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group","volume":"32","author":"Janin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2025.12.001_bib0013","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood.V124.21.3734.3734","article-title":"AG-120, an oral, selective, first-in-class, potent inhibitor of mutant IDH1, reduces intracellular 2HG and induces cellular differentiation in TF-1 R132H cells and primary Human IDH1 mutant AML patient samples treated ex vivo","volume":"124","author":"Hansen","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.12.001_bib0014","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1016\/j.clml.2025.12.001_bib0015","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","article-title":"Structure-based design and identification of FT-2102 (Olutasidenib), a potent mutant-selective IDH1 inhibitor","volume":"63","author":"Caravella","year":"2020","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.clml.2025.12.001_bib0016","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","author":"Watts","year":"2023","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.clml.2025.12.001_bib0017","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1182\/bloodadvances.2025016718","article-title":"Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome","volume":"9","author":"Cortes","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2025.12.001_bib0018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/14737159.2016.1142374","article-title":"Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory","volume":"16","author":"Kanagal-Shamanna","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.clml.2025.12.001_bib0019","series-title":"Survival and event history analysis: a process point of view","author":"Aalen","year":"2008"},{"key":"10.1016\/j.clml.2025.12.001_bib0020","unstructured":"The jamovi project (2025). jamovi (Version 2.3.21) [Computer Software]. https:\/\/www.jamovi.org. Accessed December 26, 2025."},{"issue":"1","key":"10.1016\/j.clml.2025.12.001_bib0021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with Azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2025.12.001_bib0022","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clml.2025.12.001_bib0023","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.12.001_bib0024","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2021-146932","article-title":"Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the idiome phase 2 study by the GFM Group","volume":"138","author":"Sebert","year":"2021","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2025.12.001_bib0025","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.clml.2025.12.001_bib0026","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.clml.2025.12.001_bib0027","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502504296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502504296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:46:37Z","timestamp":1773935197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502504296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S215226502504296X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}